Korro Bio's (KRRO) move to prioritize GaINac-conjugated programs that target the liver is the pragmatic approach after the "disappointing" data on its KRRO-110 product candidate, RBC Capital Markets said in a note Thursday.

The company is going into cash preservation mode by cutting its workforce by 34% across all levels in a bid to extend its cash runway for the development of KRRO-121, its next candidate as a potential treatment for patients with hyperammonemia.

Management also announced that it targets to a nominate a GalNAc-conjugated construct development candidate for alpha-1 antitrypsin deficiency, or AATD, in H1 2026.

"While the initial approach to AATD did not pan out, we think moving to GaINac makes logical sense," analysts said.

RBC downgraded Korro Bio to sector perform from outperform, and slashed its price target to $8 from $85 previously.

Shares of Korro Bio were down more than 76% in recent premarket activity Thursday.